Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights
Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript
Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
Acrivon Therapeutics Acquires Janus Kinase 1 Inhibitor ACR-525 From Aqilion AB; Terms Undisclosed
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
Acrivon Therapeutics To Present Dose Escalation Data From Its Current Phase 1/2 Trial Of ACR-2316 At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
Acrivon Therapeutics Advances ACR-7280, Showing Complete Tumor Regression In AML Models, With IND Filing Targeted For H1 2027
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.